Chiossone, Vivier et al, 2022.
Bringing natural killer cells to the clinic
J Exp Med.
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK...
Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...
Number of shares and voting rights of Innate Pharma as of august 1, 2022
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...
Innate Pharma provides update on AstraZeneca-sponsored Interlink-1 Phase 3 study
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca...
Innate Pharma to participate in upcoming investor conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...
Second Innate Pharma NK Cell Engager Selected by Sanofi as drug candidate for development
IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE ® multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate’s...
Innate Pharma to participate in upcoming investor conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that its investor relation team will participate in the following upcoming investor conference...
Herbst et al, 2022.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Innate Pharma announces IPH5201 Phase 2 study in lung cancer
Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer Innate to receive $5M milestone payment from AstraZeneca Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ”...